These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33038745)

  • 1. Establishment of an induced pluripotent stem cell line PUMCHi004-A from a hereditary transthyretin amyloid cardiomyopathy patient with transthyretin (TTR) p.Asp38Asn mutation.
    He S; Jin Y; Tian Z; Hua T; Xing H; Zhuang S; He X; Li H; Wang L; Zhang S
    Stem Cell Res; 2020 Dec; 49():102022. PubMed ID: 33038745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of an induced pluripotent stem cell line from a patient with hereditary transthyretin amyloidosis carrying transthyretin (TTR) mutation p.Phe53Val.
    Shan H; Ye J; Hai Ping X; XinYue H; ShuYang Z
    Stem Cell Res; 2020 Oct; 48():101940. PubMed ID: 32858486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of an induced pluripotent stem cell line (ESi107-A) from a transthyretin amyloid cardiomyopathy (ATTR-CM) patient carrying a p.Ser43Asn mutation in the TTR gene.
    Montero-Calle P; Flandes-Iparraguirre M; Kuebler B; Arán B; Larequi E; Anaut I; Coppiello G; Aranguren XL; Veiga A; Elorz MTB; de Yébenes MG; Gavira JJ; Prósper F; Iglesias-García O; Vega MMM
    Stem Cell Res; 2023 Sep; 71():103189. PubMed ID: 37660554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation.
    Bonilauri B; Shin HS; Htet M; Yan CD; Witteles RM; Sallam K; Wu JC
    Stem Cell Res; 2023 Oct; 72():103215. PubMed ID: 37788558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of two induced pluripotent stem cell lines from hereditary amyloidosis patients with polyneuropathy carrying heterozygous transthyretin (TTR) mutation.
    Melesio J; Bonilauri B; Li A; Pang PD; Liao R; Witteles RM; Wu JC; Sallam K
    Stem Cell Res; 2024 Feb; 74():103265. PubMed ID: 38100909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.
    Tini G; Vianello PF; Gemelli C; Grandis M; Canepa M
    J Cardiovasc Transl Res; 2019 Dec; 12(6):514-516. PubMed ID: 30604309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease.
    Giadone RM; Liberti DC; Matte TM; Rosarda JD; Torres-Arancivia C; Ghosh S; Diedrich JK; Pankow S; Skvir N; Jean JC; Yates JR; Wilson AA; Connors LH; Kotton DN; Wiseman RL; Murphy GJ
    Stem Cell Reports; 2020 Aug; 15(2):515-528. PubMed ID: 32735824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DISCOVERY: prevalence of transthyretin (
    Akinboboye O; Shah K; Warner AL; Damy T; Taylor HA; Gollob J; Powell C; Karsten V; Vest J; Maurer MS
    Amyloid; 2020 Dec; 27(4):223-230. PubMed ID: 32456532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population.
    Lavigne-Moreira C; Marques VD; Gonçalves MVM; de Oliveira MF; Tomaselli PJ; Nunez JC; do Nascimento OJM; Barreira AA; Marques W
    J Peripher Nerv Syst; 2018 Jun; 23(2):134-137. PubMed ID: 29520877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).
    Klaassen SHC; Lemmink HH; Bijzet J; Glaudemans AWJM; Bos R; Plattel W; van den Berg MP; Slart RHJA; Nienhuis HLA; van Veldhuisen DJ; Hazenberg BPC
    Cardiovasc Pathol; 2017; 29():19-22. PubMed ID: 28460244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary transthyretin cardiac amyloidosis proven by endomyocardial biopsy: a single-centre retrospective study and literature review.
    Yu TP; Hou J; Yang TJ; Chen XQ; Chen YC
    Acta Cardiol; 2024 Jun; 79(4):436-443. PubMed ID: 37768132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transthyretin Glu54Leu - an unknown mutation within the Swedish population associated with amyloid cardiomyopathy and a unique fibril type.
    Hellman U; Lång K; Ihse E; Jonasson J; Olsson M; Lundgren HE; Pilebro B; Westermark P; Wixner J; Anan I
    Scand J Clin Lab Invest; 2019 Oct; 79(6):372-376. PubMed ID: 31169435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
    Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
    Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis.
    Leung A; Nah SK; Reid W; Ebata A; Koch CM; Monti S; Genereux JC; Wiseman RL; Wolozin B; Connors LH; Berk JL; Seldin DC; Mostoslavsky G; Kotton DN; Murphy GJ
    Stem Cell Reports; 2013; 1(5):451-63. PubMed ID: 24286032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S).
    Nakase T; Yamashita T; Matsuo Y; Nomura T; Sasada K; Masuda T; Misumi Y; Takamatsu K; Oda S; Furukawa Y; Obayashi K; Matsui H; Ando Y; Ueda M
    Intern Med; 2019 Sep; 58(18):2695-2698. PubMed ID: 31178489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).
    Judge DP; Kristen AV; Grogan M; Maurer MS; Falk RH; Hanna M; Gillmore J; Garg P; Vaishnaw AK; Harrop J; Powell C; Karsten V; Zhang X; Sweetser MT; Vest J; Hawkins PN
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):357-370. PubMed ID: 32062791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.